oestrogen
ApprovedSmall molecule
Novo Nordiskoestrogen is one of 19 small molecule programs targeting Turner syndrome. It is currently in Approved.
1
Indications
2
Total Trials
0
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Turner Syndrome
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Depo-Provera
Eli LillyPhase 3
Micronized Progesterone
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Approved
Estinyl
OOrganon and Co
Phase 3
R-Hgh
Merck & Co.Approved
Voxzogo
BioMarin PharmaceuticalPhase 2
Growth Hormone
PfizerPhase 2
Estradiol Valerate
BayerPhase 2
oestrogen
Novo NordiskApproved
Oxandrolone
PPar Pharmaceutical, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for oestrogen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company